source
- Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy supportOrphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…
- RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo TherapeuticsRallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…